Efficacy of Danshen Class Injection in the Treatment of Acute Cerebral Infarction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials

Table 2

Results of the network meta-analysis of activities of daily living function (lower left quarter) and whole blood high shear viscosity (upper right quarter).

A	-1.32; (-2.37, -0.27)	-0.42; (-1.48, 0.64)	-1.55; (-2.37, -0.74)	-1.50; (-3.82, 0.81)	-1.66; (-3.11, -0.21)	-0.72; (-1.75, 0.29)	-0.57; (-2.65, 1.5)
1.63; (-5.61, 8.88)	B	0.90; (-0.50, 2.31)	-0.23; (-1.43, 0.98)	-0.17; (-2.69, 2.30)	-0.34; (-2.13, 1.43)	0.60; (-0.86, 2.06)	0.75; (-1.59, 3.09)
10.83; (4.68, 16.87)	9.20; (-0.07, 18.32)	C	-1.13; (-1.95, -0.33)	-1.08; (-3.15, 0.96)	-1.24; (-3.02, 0.59)	-0.30; (-1.76, 1.15)	-0.15; (-2.5, 2.2)
10.55; (7.42, 13.63)	8.92; (1.74, 16.10)	-0.28; (-6.79, 6.30)	D	0.05; (-2.17, 2.24)	-0.11; (-1.75, 1.54)	0.83; (-0.46, 2.12)	0.98; (-1.25, 3.23)
9.53; (5.48, 13.60)	7.90; (0.82, 14.96)	-1.30; (-8.08, 5.61)	-1.02; (-5.92, 3.99)	E	-0.16; (-2.85, 2.56)	0.77; (-1.73, 3.32)	0.92; (-2.21, 4.05)
16.53; (6.94, 26.17)	14.91; (2.97, 26.98)	5.71; (-5.55, 17.14)	5.99; (-4.17, 16.14)	7.01; (-3.34, 17.37)	F	0.94; (-0.82, 2.71)	1.09; (-1.42, 3.61)
7.37; (2.35, 12.45)	5.74; (-3.14, 14.48)	-3.46; (-11.26, 4.55)	-3.18; (-9.11, 2.82)	-2.16; (-8.66, 4.27)	-9.17; (-19.95, 1.71)	G	0.15; (-2.15, 2.44)
9.73; (4.00, 15.40)	8.11; (-1.05, 17.32)	-1.10; (-9.46, 7.35)	-0.82; (-7.37, 5.76)	0.21; (-6.83, 7.23)	-6.80; (-18.03, 4.38)	2.37; (-5.32, 10.08)	H

A: WM; B: Danshen injection + WM; C: Fufang Danshen injection + WM; D: Danhong injection + WM; E: Danshenchuanxiongqin injection + WM; F: Sodium Tanshinone IIA Sulfonate injection + WM; G: Salvianolate injection + WM; H: Danshen Salvianolic Acids injection + WM. The result underlined meant it had statistical significant.